Childhood leukaemia study groups have focused on augmenting chemotherapy in combination with either Janus kinase 2 (JAK2) specific drugs, such as ruxolitinib, or ABL/platelet-derived growth factor receptor (PDGF-R) inhibitors, such as imatinib or dasatinib. Here, JAK2 is linked to leukemia.